DataMeds AI, Inc MEDS
3.11
(0.39)
(11.14%)
as of 25 Sep
- Market cap
- $10.9M
- P/E
- 0.0×
Follow MEDS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 949.27% | 1,447.25% | 3,545.16% | (4,010.50%) |
+7 more TTM periods Free account |
|
| (202.97%) | (173.68%) | (230.71%) | (294.64%) | ||
ROIC |
0.00% | (702.13%) | (532.81%) | (143.70%) | |
Return on Tangible Assets |
262.67% | 261.96% | 378.86% | 395.66% | |
Average Days of Receivables |
54.61 | 25.91 | 17.79 | 11.78 | |
Free Cash Flow per Share |
(5.69) | (6.56) | (8.27) | (5.07) | |
Free Cash Flow |
(14.66) | (13.73) | (11.74) | (7.55) | |
Capital Expenditures |
(0.92) | (0.81) | (0.88) | (0.36) | |
Piotroski F-Score |
1.00 | 1.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(517.09%) | (208.62%) | (97.95%) | (18.04%) | |
Accounts Receivable Turnover |
3.09 | 5.66 | 9.56 | 47.45 | |
Accounts Payable Turnover |
1.38 | 2.08 | 3.30 | 5.47 | |
Inventory Turnover |
2.90 | 3.67 | 5.34 | 0.00 | |
Average Days of Payables |
301.58 | 208.79 | 143.36 | 121.31 | |
Days of Inventory on Hand |
36.04 | 29.81 | 20.10 | 87.09 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
599.71% | 328.83% | 306.61% | 210.60% | |
Share Based Compensation of Revenue |
357.07% | 202.21% | 234.79% | 162.92% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.16 | 0.17 | 0.11 | 0.09 | |
Depreciation/Fixed assets |
99.10 | 83.54 | 68.95 | 13.00 | |
Capex/Depreciation |
(0.05) | (0.05) | (0.06) | (0.10) | |
Revenue per Share |
3.12 | 6.71 | 16.44 | 22.91 | |
Operating CF per Share |
(5.33) | (6.18) | (7.65) | (4.83) | |
Capex per Share |
(0.36) | (0.39) | (0.62) | (0.24) | |
Capex to Sales |
0.12 | 0.06 | 0.04 | 0.01 | |
Net Profit Margin |
(1,100.29%) | (545.72%) | (433.95%) | (228.17%) |
Columns are period end dates